BAO PHARMA-B (02659) surged more than 10% during intraday trading before paring gains, with shares last up 5.56% at HK$14.63 on turnover of HK$12.16 million.
The first half of the year marks a pivotal commercialization phase for BAO PHARMA-B, as the company accelerates into a growth trajectory driven by both commercial expansion and international development. According to Guosen Securities, KJ017 is slated for domestic market approval in March 2026, targeting use as an aid for subcutaneous infusion, with data from two Phase 3 clinical trials published in the European Journal of Pharmaceutics and Biopharmaceutics. The company has been actively expanding partnerships, with more than 60 collaborators utilizing KJ017 for product development as of the 2026 interim report, spanning projects from early-stage research to clinical development stages.
Additionally, the New Drug Application (NDA) for KJ103, intended for desensitization therapy prior to kidney transplantation, was submitted and accepted by the National Medical Products Administration in May 2026. A Phase 3 clinical study for desensitization treatment in highly sensitized kidney transplant patients achieved its primary endpoint in March 2026, demonstrating rapid and highly successful desensitization effects alongside a favorable safety profile. Furthermore, data from a Phase 2 clinical study targeting anti-GBM disease was presented at the European Renal Association Congress in June 2026, initially showcasing its clinical value. Since its market launch, SJ02 has secured online procurement platform listings and market access across 29 provinces in China through partner-driven promotional efforts, reaching over 70 medical institutions.
Comments